New drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT07245797

Not yet recruiting Disease control Sponsor: Zhimin Shao Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the drug inavolisib to a standard pre-surgery regimen (pertuzumab, trastuzumab, and nab-paclitaxel) can improve outcomes for people with a specific genetic mutation (PIK3CA) in HER2-positive early breast cancer. About 164 participants will receive either the combo with or without inavolisib before surgery. The main goal is to see if the cancer disappears completely by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inavolisib plus pertuzumab and trastuzumab (subcutaneous) and nab-paclitaxel
What this could lead to: If successful, this could point toward a more effective pre-surgery treatment for a specific type of breast cancer, potentially increasing the chance of no cancer remaining at surgery.
What could go wrong: This is a small, early-phase (phase 2) trial, so results may not confirm benefit. Adding inavolisib may also increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.